ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) just released its latest first-quarter results and things are looking bullish. Revenues beat expectations coming in atUS$7.6m, ahead of estimates by 9.2%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.16 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ClearPoint Neuro after the latest results.

View our latest analysis for ClearPoint Neuro

After the latest results, the three analysts covering ClearPoint Neuro are now predicting revenues of US$30.5m in 2024. If met, this would reflect a meaningful 17% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 16% from last year to US$0.63. Before this latest report, the consensus had been expecting revenues of US$30.3m and US$0.76 per share in losses. Although the revenue estimates have not really changed ClearPoint Neuro'sfuture looks a little different to the past, with a cut to the loss per share forecasts in particular.

There's been no major changes to the consensus price target of US$10.00, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic ClearPoint Neuro analyst has a price target of US$11.00 per share, while the most pessimistic values it at US$9.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 23% growth on an annualised basis. That is in line with its 20% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.1% per year. So it's pretty clear that ClearPoint Neuro is forecast to grow substantially faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at US$10.00, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for ClearPoint Neuro going out to 2026, and you can see them free on our platform here..

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for ClearPoint Neuro that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.